Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
Фаза 2
Прекращено
NCT05584202
| Заболевание | SARS-CoV-2 |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | ModernaTX, Inc. |
|---|
| Статус | Прекращено |
|---|
| Участники | 68 участн. |
|---|
| Вмешательство | mRNA-1273.214 |
|---|
| Дата начала | 30.09.2022 |
|---|
| Дата завершения | 15.11.2024 |
|---|
| Публикация результатов | 26.11.2025 |
|---|
Кратко
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Injection
Day 1 up to 7 days after first vaccination (up to Day 8) · Participants
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 23 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 8 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 3 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs After Second Injection
Day 57 up to 7 days after second vaccination (up to Day 64) · Participants
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 18 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 6 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 2 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) After Any Injection
Day 1 up to 28 days after any vaccination (up to Day 85) · Participants
| mRNA-1273.214 5 μg (Safety Set) | 24 Participants |
|---|
| mRNA-1273.214 10 μg (Safety Set) | 8 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.